Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11076402 | 0.68 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL9699968 | 0.67 | LIPG (0.69) | KCNH2LIPG | |
| SCHEMBL10980560 | 0.67 | LIPG (0.69) | KCNH2LIPG | |
| SCHEMBL2511612 | 0.67 | LIPG (0.69) | KCNH2LIPG | |
| SCHEMBL18496530 | 0.67 | LIPG (0.69) | KCNH2LIPG | |
| SCHEMBL1343771 | 0.67 | LIPG (0.69) | KCNH2LIPG | |
| SCHEMBL15809821 | 0.67 | LIPG (0.69) | KCNH2LIPG | |
| SCHEMBL7534048 | 0.67 | LIPG (0.69) | KCNH2LIPG | |
| SCHEMBL6679764 | 0.67 | LIPG (0.69) | KCNH2LIPG | |
| SCHEMBL10755599 | 0.67 | LIPG (0.69) | KCNH2LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904059-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007013936-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | WYETH (US) | 2007-02-01 | — | — | WO | disclosed |